Yuki Yoshikawa
Hiroshima Prefectural Hospital
ORCID: 0000-0001-8834-5051Also affiliated with Osaka University of Pharmaceutical Sciences
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 5 papers. Top paper: “Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan”.
Kazumasa Komura, Wataru Fukuokaya, Takahiro Kimura, Kazuhiro Takahashi, Yusuke Yano +18 more
Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa +10 more
Goutam Chakraborty, Subhiksha Nandakumar, Ying Z. Mazzu, Konrad H. Stopsack, Yuki Yoshikawa +3 more
Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa +10 more
Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa +10 more